Collectives of diagnostic biomarkers identify high-risk subpopulations of hematuria patients: Exploiting heterogeneity in large-scale biomarker data

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Emmert Streib, Frank ^a   Abogunrin, Funso ^a   de Matos Simoes, Ricardo ^a   Duggan, Brian ^b   Ruddock, Mark W ^c   Reid, Cherith N ^c   Roddy, Owen ^a   White, Lisa ^a   O'Kane, Hugh F ^b   O'Rourke, Declan ^b   Anderson, Neil H ^d   Nambirajan, Thiagarajan ^b   Williamson, Kate E ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c Randox Laboratories Ltd   (United Kingdom)

^d ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

biomarker; feature selection; hematuria; hierarchical clustering; proteinuria; Random Forests Classifier; risk stratification; urothelial cancer

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CREATININE; CYTOKERATIN 18; D DIMER; EPIDERMAL GROWTH FACTOR; GELATINASE B; HYALURONIDASE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ARTICLE; BLADDER CANCER; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; CYTOLOGY; DEMOGRAPHY; FEMALE; HEMATURIA; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PROTEINURIA; SMOKING; SYSTEMS BIOLOGY; UROGENITAL TRACT TUMOR;

EID: 84872268345     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-12     Document Type: Article

References (30)

1. Mostafid H, Persad R, Kockelbergh R, Fawcett D. Is it time to re-design the hematuria clinic?. BJU Int 2010, 105:585-588. 10.1111/j.1464-410X.2009.09108.x, 20002672.
2. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come?. CA Cancer J Clin 2010, 60:244-272. 10.3322/caac.20077, 20566675.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
4. Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 2007, 4:e284. 10.1371/journal.pmed.0040284, 1989749, 17896857.
5. van der Aa MN, Steyerberg EW, Bangma C, van Rhijn BW, Zwarthoff EC, van der Kwast TH. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. J Urol 2010, 183:76-80. 10.1016/j.juro.2009.08.150, 19913254.
6. Lotan Y, Elias K, Svatek RS, Bagrodia A, Nuss G, Moran B, Sagalowsky AI. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol 2009, 182:52-57. 10.1016/j.juro.2009.02.142, 19450825.
7. Kinders R, Jones T, Root R, Bruce C, Murchison H, Corey M, Williams L, Enfield D, Hass GM. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998, 4:2511-2520.
8. Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997, 158:2098-2101. 10.1016/S0022-5347(01)68166-7, 9366321.
9. Abogunrin F, O'Kane HF, Ruddock MW, Stevenson M, Reid CN, O'Sullivan JM, Anderson NH, O'Rourke D, Duggan B, Lamont JV, Boyd RE, Hamilton P, Nambirajan T, Williamson KE. The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. Cancer 2011, 118:2641-2650.
10. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 2005, 23:5746-5756. 10.1200/JCO.2005.01.598, 16110031.
11. Margel D, Pesvner-Fischer M, Baniel J, Yossepowitch O, Cohen IR. Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. Eur Urol 2011, 59:113-119. 10.1016/j.eururo.2010.10.008, 20970244.
12. Vidal M. A unifying view of 21st century systems biology. FEBS Lett 2009, 583:3891-3894. 10.1016/j.febslet.2009.11.024, 19913537.
13. Emmert-Streib F, Glazko GV. Network biology: a direct approach to study biological function. Wiley Interdiscip Rev Syst Biol Med 2011, 3:379-391. 10.1002/wsbm.134, 21197659.
14. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC, . Standards for Reporting of Diagnostic Accuracy Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003, 49:1-6. 10.1373/49.1.1, 12507953, Standards for Reporting of Diagnostic Accuracy.
15. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC, Lijmer JG, . Standards for Reporting of Diagnostic Accuracy The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003, 49:7-18. 10.1373/49.1.7, 12507954, Standards for Reporting of Diagnostic Accuracy.
16. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007, 177:361-368. 10.1503/cmaj.061590, 1942114, 17698825.
17. Fitzgerald SP, Lamont JV, McConnell RI, Benchikh el O. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 2005, 51:1165-1176. 10.1373/clinchem.2005.049429, 15890889.
18. Theodoridis S. Pattern Recognition 2003, Amsterdam; London: Academic Press, 2.
19. Breiman L. Bagging predictors. Machine Learning 1996, 24:123-140.
20. Zhang H, Singer BH. Recursive Partitioning and Applications 2010, New York: Springer.
21. Haematuria guidelines. , http://www.baus.org.uk/AboutBAUS/publications/haematuria-guidelines
22. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int 2011, 80:806-821. 10.1038/ki.2011.198, 21697815.
23. Goldstein SL. Acute kidney injury biomarkers: renal angina and the need for a renal troponin I. BMC Med 2011, 9:135. 10.1186/1741-7015-9-135, 3287120, 22189039.
24. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2008, 108:389-397. 10.1007/s10549-007-9619-3, 17554627.
25. Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, Jardine M, Gallagher M, Turnbull F, Chalmers J, Craig J, Huxley R. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 2008, 5:e207. 10.1371/journal.pmed.0050207, 2570419, 18942886.
26. Mason RA, Morlock EV, Karagas MR, Kelsey KT, Marsit CJ, Schned AR, Andrew AS. EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis 2009, 30:1155-1160. 10.1093/carcin/bgp077, 2704279, 19372140.
27. McShane LM. Statistical challenges in the development and evaluation of marker-based clinical tests. BMC Medicine 2012, 10:52. 10.1186/1741-7015-10-52, 3379945, 22642713.
28. Marchio C, Dowsett M, Reis-Filho JS. Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box. BMC Medicine 2011, 9:41. 10.1186/1741-7015-9-41, 3102629, 21504565.
29. Ferrante di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PM, Deeks JJ. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ 2012, 344:e686. 10.1136/bmj.e686, 22354600.
30. Liu ET. Systems Biomedicine 2010, Boston: Academic Press.